AP Pharma Announces the Allowance of Three Patents Covering APF530

A.P. Pharma (

) announced Tuesday that the United States Patent and Trademark Office has allowed three new patents covering the Company's lead product candidate, APF530, which is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. The newly allowed patents, when issued, will extend the patent life around APF530 through 2024. “The newly allowed patents are instrumental in bolstering APF530's overall patent life and will extend the intellectual property protection surrounding the product through 2024,” said John B. Whelan, A.P. Pharma's president and chief executive officer. “A.P. Pharma continues to make advancements related to APF530 beyond clinical and regulatory development, and the allowance of these patents provides added strength to the APF530 patent estate and will help support the product's longevity.”